| The United States of America, as represented by the Secretary, Dept. of Health and Human Services Patent applications |
| Patent application number | Title | Published |
|---|
| 20120134971 | ENGINEERED BIOLOGICAL PACEMAKERS - Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed. | 05-31-2012 |
| 20120094896 | INHIBITORS OF VIRAL INTEGRASE AND METHODS OF USE - Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors. | 04-19-2012 |
| 20120004133 | METHOD FOR THE DIAGNOSIS OF AGE-ASSOCIATED VASCULAR DISORDERS - Methods for determining if a subject has or is susceptible to having an age-associated vascular disorder are disclosed. The method includes determining if the subject exhibits altered expression of a product of one or more of the genes listed in Table 1 relative to a control level of expression of the gene product. Altered expression of one or more of the genes listed in Table 1 indicates that the subject has or is susceptible to having an age-associated vascular disorder. In specific examples the gene product is a product of the MFG-E8 and an increase in expression indicates the subject has or is susceptible to having an age-associated vascular disorder. | 01-05-2012 |
| 20110313029 | DIAGNOSTIC AND THERAPEUTIC USES OF GNPTAB, GNPTG, AND NAGPA IN STUTTERING - The allelic variants or mutations in three genes: GNPTAB, GNPTG and NAGPA, that correlate with stuttering in humans, as well as the encoded mutated polypeptides and related vectors, host cells, antibodies, antibody-producing cell lines and methods of diagnosing, prognosticating and treating stuttering are provided. | 12-22-2011 |
| 20110190240 | NUCLEAR FACTOR KAPPA B PATHWAY INHIBITOR COMPOSITION AND USE OF SAME - An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I)a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds. | 08-04-2011 |
| 20110183334 | METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION - The invention provides methods of detecting abnormal cells in a sample using the radial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the radial position of one or more genes within the nucleus of a cell. | 07-28-2011 |
| 20100322910 | METHODS OF OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided. | 12-23-2010 |
| 20100291037 | IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES - This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC. | 11-18-2010 |
| 20100254899 | RADIOLABELED AFFIBODY MOLECULES - The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from | 10-07-2010 |
| 20100240578 | ANTI-H5N1 INFLUENZA ACTIVITY OF THE ANTIVIRAL PROTEIN CYANOVIRIN - The invention is directed to a method of inhibiting prophylactically or therapeutically an H5N1 viral infection in a host, which method comprises administering to the host an anti-viral effective amount of an antiviral protein comprising the amino acid sequence of SEQ ID NO: 1 or a nucleic acid encoding the antiviral protein, as well as antiviral portions, variants, and conjugates thereof. | 09-23-2010 |
| 20100209386 | AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA) - The invention provides a peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention also provides methods comprising the administration of the peptide. | 08-19-2010 |
| 20100168165 | METHOD OF TREATING DISEASE INVOLVING MYELIN AND/OR AXONAL LOSS - Disclosed is a method of treating a disease involving myelin and/or axonal loss, such as a demyelinating disease, in a mammal comprising administering a compound of formula I | 07-01-2010 |
| 20100136056 | NOVEL INSERTION SITES IN POX VECTORS - The present invention provides novel insertion sites for introducing DNA into pox vectors. | 06-03-2010 |
| 20100056776 | METHOD OF PREPARING MACROMOLECULAR CONTRAST AGENTS AND USES THEREOF - Disclosed are methods of preparing a macromolecular conjugated ligand and a metal complex thereof. The metal complex is targeted for use as a contrast agent, for example, in MRI. The method of preparing a macromolecular conjugated ligand comprises: (a) providing a compound of formula (I) | 03-04-2010 |
| 20100040626 | METHODS FOR DETECTING AND TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER - The invention provides a method of determining a susceptibility of a subject for development of ADHD. The method comprises obtaining a sample from the subject, analyzing the sample for an ADHD susceptibility haplotype of LPHN3 receptor which is associated with at least one genetic marker selected from the group consisting of rs7678046, rs1901223, rs6813183, and rs1355368, and determining if the subject has a susceptibility to develop ADHD, whereby the presence of the haplotype having one or more of the genetic markers is indicative of a susceptibility to develop ADHD. The invention also provides methods of treating ADHD. | 02-18-2010 |
| 20100015113 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 01-21-2010 |
| 20090304657 | CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR. | 12-10-2009 |
| 20090068141 | AUTOLOGOUS NATURAL KILLER CELLS AND LYMPHODEPLETING CHEMOTHERAPY FOR THE TREATMENT OF CANCER - The invention provides a simple, cost-effective method of preparing a composition comprising natural killer (NK) cells useful for administering to a human. The method comprises (i) depleting CD3 | 03-12-2009 |
